Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

The 39 year-old star of TV, film and stage has battled with the potentially fatal condition since his early 20s, but has ...

One of the primary drivers is the increasing need for prefilled syringes, which are preferred for their convenience, safety, and ease of use, especially in self-administration of medications like ...